In a study involving advanced CRC patients, Sanger sequencing confirmed mutation status in conjunction with pyrosequencing, revealing a PIK3CA mutation rate of 7.5% in exon 9% and 3.6% in exon 20 (Price et al., 2015). The gene discussed is PIK3CA; the disease is colorectal carcinoma.